Apollo Therapeutics
https://apollotherapeutics.comPortfolio of pharmaceutical research and discovery.
Summary
Insights
This section hypothesizes why Apollo Therapeutics can be a $10 billion dollar company in 10 years, in 10 lines or less.
Apollo Therapeutics is building a diversified clinical-stage portfolio of assets in cell signaling, cell stress response, and immunology, backed by specialist long-term investors and collaborations with five of the world’s leading research universities. They initially started as a partnership between three top research organizations and three global pharmaceutical companies with an initial commitment of $50M. It's potential lies in its unique portfolio approach to drug development, leveraging cutting-edge research from prominent academic institutions and the industry expertise of pharmaceutical giants. Their focus on high-value markets and a broad range of programs, coupled with a lean operating model, positions them well for innovative drug discovery and development.
Total funding Amount
Fundraising History
-
Jan 02 '24 Series C$34M
-
Sep 06 '23 Series C$230M
-
Jun 17 '21 Series C$120M
Investors
-
Series C
-
Series C
-
Series C